{"id":"W2883260430","doi":"10.1007/s12028-018-0575-z","title":"Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)]","year":2018,"lang":"en","type":"article","venue":"Neurocritical Care","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Nimodipine; Tolerability; Anesthesia; Clinical endpoint; Subarachnoid hemorrhage; Placebo; Randomized controlled trial; Multicenter trial; Regimen; Clinical trial; Adverse effect; Neurointensive care; Dosing; Surgery; Internal medicine; Multicenter study","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00667529,0.004188413,0.006491504,0.0009646441,0.001911366,0.002208555,0.003397198,0.005285191,0.03830298],"category_scores_gemma":[0.007034828,0.001740191,0.002280625,0.001161132,0.00258569,0.002006307,0.0007708017,0.006850182,0.007443097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002164943,"about_ca_system_score_gemma":0.007550481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002256566,"about_ca_topic_score_gemma":0.006843593,"domain_scores_codex":[0.9977422,0.001065578,0.0002287481,0.0003558565,0.0002781581,0.000329468],"domain_scores_gemma":[0.9968331,0.0005346097,0.000685309,0.0003650442,0.0005678256,0.001014159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9767784,0.006787023,0.0002007555,0.001533952,0.0005966275,0.00004710018,0.00005324063,0.0002440787,0.001532567,0.000393474,0.004409675,0.007423089],"study_design_scores_gemma":[0.987134,0.009387828,0.0004390541,0.00007721731,0.0001519637,0.00001190457,0.00001010965,0.0001750627,0.000164842,0.0001377372,0.002297569,0.00001258533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1397181,0.004750942,0.007109542,0.002281178,0.002847233,0.8142239,0.01660455,0.001131913,0.01133265],"genre_scores_gemma":[0.2022447,0.00376637,0.01746622,0.006191366,0.001666353,0.7426357,0.01042983,0.000195745,0.01540374],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03830298,"threshold_uncertainty_score":0.1281363,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02655586471223254,"score_gpt":0.3537777520877344,"score_spread":0.3272218873755019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}